(Source: Business Wire)
pSivida Corp. (NASDAQ:PSDV), (ASX:PVA), (FF:PV3), a leading drug
delivery company, today announced that its financial results for the
fourth quarter and fiscal year ended June 30, 2009, will be released
after market close on Thursday, September 24, 2009, followed the same
day by a conference call and live webcast scheduled for 4:30 p.m. ET.
The conference call may be accessed by dialing (888) 679-8037 from the
U.S. and Canada, or (617) 213-4849 from international locations,
passcode 81567007. Interested parties may pre-register to participate at www.theconferencingservice.com/prereg,
registration key PYARVPDW4.
A replay of the call will be available approximately two hours following
the end of the call through October 1, 2009. The replay may be accessed
by dialing (888) 286-8010 within the U.S. and Canada or (617) 801-6888
from international locations, passcode 82397201.
The conference call will be available via the Internet at www.psivida.com
and will also be distributed through the Thomson StreetEvents Network.
Individual investors can listen to the call via www.earnings.com
and Institutional investors can access the call via www.streetevents.com.
The call will be archived and accessible on the Web site for
approximately 30 days.
Listeners are encouraged to login at least 15 minutes prior to the start
of the scheduled presentation to register, download and install any
necessary audio software.
About pSivida Corp.
pSivida is a world leader in the development of miniaturized,
injectable, drug delivery systems for the eye. pSivida's lead
development product, Iluvien®, delivers fluocinolone
acetonide (FA) for the treatment of diabetic macular edema (DME).
Formerly known as Medidur FA for DME, Iluvien is in fully recruited
Phase III clinical trials. pSivida has licensed certain drug delivery
technology to Alimera Sciences, Inc. for the development of Iluvien and
certain other ophthalmic products. pSivida also has two products
approved by the Food and Drug Administration (FDA): Retisert®
for the treatment of uveitis and Vitrasert® for the treatment
of AIDS-related cytomegalovirus (CMV) retinitis. pSivida has licensed
both of these products and the technologies underlying them to Bausch &
Lomb Incorporated. pSivida has a worldwide collaborative research and
license agreement with Pfizer Inc. under which Pfizer may develop
additional ophthalmic products.
pSivida owns the rights to develop and commercialize a modified form of
silicon known as BioSilicon, which has potential therapeutic
applications.
